Botensilimab drug page Clinical trials

Trials with Botensilimab

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

19Trials
12Recruiting
10Countries
2.465Planned patients

Showing 1–19 of 19

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
Recruiting Phase 2 20 patients NCT07551596

This phase II trial tests the effect of the botensilimab in combination with balstilimab in treating patients with stage II/III colorectal adenocarcinoma with detectable circulating tumor (ct) deoxyribonucleic acid (DNA) in the blood. Immu…

United States May 2027 – Aug 2029 Interventional
Combined with: Balstilimab
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
Recruiting Phase 2 100 patients NCT07595874

This phase II trial tests how well giving botensilimab and balstilimab prior or to surgery (neoadjuvent) works for the treatment of colorectal cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distan…

United States Dec 2026 – May 2027 Interventional
Combined with: Balstilimab
RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer
Recruiting Phase 2 16 patients NCT07735624

This is a multi-site, prospective, non-randomized phase 2 study evaluating neoadjuvant botensilimab in combination with balstilimab for patients with microsatellite stable (MSS) / mismatch repair proficient (MMRp) early rectal cancer stage…

United States Sept 2026 – Dec 2032 Interventional
Combined with: Balstilimab
BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases
Recruiting Phase 2 17 patients NCT07550088

The goal of this clinical trial is to learn whether the combination of balstilimab, botensilimab, and agenT-797 is safe and effective in treating adults with previously treated metastatic colorectal cancer that is microsatellite stable (pM…

United States Jun 2026 – Dec 2028 Interventional
Combined with: AGENT-797Balstilimab
Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
Recruiting Phase 1 15 patients NCT07128355

This is a single-arm pilot feasibility study evaluating the combination of Botensilimab and Balstilimab with Radiation Therapy (RT) in Non-Microsatellite Instability High (MSI-H) or Proficient Mismatch Repair (pMMR) chemorefractory colorec…

United States May 2026 – Sept 2027 Interventional
Combined with: Balstilimab
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
Recruiting Phase 2 284 patients NCT07227636

The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colorectal cancer or c…

United States Nov 2025 – Nov 2030 Interventional
Combined with: Balstilimab
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
Recruiting Phase 2 26 patients NCT06780787

This phase II trial tests how well fluorouracil, oxaliplatin and leucovorin calcium (folinic acid) (FOLFOX) with botensilimab and balstilimab given before surgery (neoadjuvant) works in treating patients with rectal adenocarcinoma that has…

United States May 2025 – Nov 2027 Interventional
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
Recruiting Phase 2 40 patients NCT06843434

The purpose of this study is to find out whether the combination of botensilimab and balstilimab (BOT/BAL) is a safe and effective treatment that causes few or mild side effects for people with mismatch repair proficient (MMRp)/microsatell…

United States Feb 2025 – Feb 2028 Interventional
Combined with: Balstilimab
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
Recruiting Phase 1 15 patients NCT06336902

This phase Ib trial tests the safety, side effects, and effectiveness of botensilimab, and balstilimab in combination with a fasting mimicking diet and high dose vitamin C in treating patients with KRAS-mutant metastatic colorectal cancer.…

United States Jan 2025 – Jan 2028 Interventional
Combined with: Balstilimab
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Recruiting Phase 1 54 patients NCT06411691

Phase 1b study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with Balstilimab and Botensilimab for unresectable or metastatic mismatch repair-proficient (MMR-p) colorect…

United States Nov 2024 – Nov 2030 Interventional
Combined with: Balstilimab
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Recruiting Phase 2 24 patients NCT06300463

The goal of this clinical trial is to to learn about different combinations of immunotherapy in patients with colorectal cancer whose cancer has spread to their liver and are planning to have surgery to remove tumor metastases from their l…

United States Mar 2024 – Dec 2027 Interventional
Combined with: AGEN1423Balstilimab
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Recruiting Phase 2 197 patients NCT05845450

This is a window-of-opportunity umbrella platform trial enrolling non-metastatic resectable colorectal patients selected for the presence of a specific targetable molecular alteration. The study aims to test the activity of specific target…

Italy May 2023 – May 2028 Interventional
Botensilimab and Balstilimab Optimization in Colorectal Cancer
Ongoing, not recruiting Phase 2 16 patients NCT06268015

This is a single-arm, interventional, pilot clinical trial. Fifteen evaluable patients will have tumor-informed ctDNA testing at baseline and start botensilimab and balstilimab treatment. They will receive botensilimab and balstilimab in 6…

United States Nov 2024 – Jul 2028 Interventional
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
Ongoing, not recruiting Phase 1 28 patients NCT05672316

This phase I/II trial tests how well botensilimab, balstilimab, and regorafenib works in treating patients with microsatellite stable colorectal cancer that has spread from where it first started (primary site) to other places in the body …

United States May 2023 – Dec 2026 Interventional
Combined with: BalstilimabRegorafenib
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
Ongoing, not recruiting Phase 1 20 patients NCT05627635

This phase I/II trial tests the safety, side effects, best dose, and efficacy of FOLFOX and bevacizumab in combination with botensilimab and balstilimab (3B-FOLFOX) in treating patients with microsatellite stable (MSS) colorectal cancer th…

United States May 2023 – Jun 2027 Interventional
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Ongoing, not recruiting Phase 2 234 patients NCT05608044

This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participant…

United States, Belgium, Brazil, France and 4 more Nov 2022 – Sept 2029 Interventional
Combined with: Balstilimab
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Ongoing, not recruiting Phase 1 499 patients NCT03860272

This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-ly…

United States, United Kingdom Mar 2019 – Dec 2027 Interventional
Combined with: Balstilimab
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Finished Phase 3 834 patients NCT07152821

This study is being done to answer the main question of: Do patients with colorectal cancer that cannot be removed by surgery, that is treated with two new immunotherapy drugs, botensilimab and balstilimab, live longer? Other important que…

Canada, France Mar 2026 – Jun 2029 Interventional
Combined with: Balstilimab
Combination Immunotherapy in Colorectal Cancer
Finished Phase 2 26 patients NCT05571293

This is a pilot study to see whether a combination of two investigational drugs that target the immune system can be given to people with colorectal cancer before surgically removing the tumor. This study is also being done to see what sid…

United States Mar 2023 – Jul 2026 Interventional
Combined with: Balstilimab

Where the recruiting trials are